Media
Media
Our latest announcements
Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV
10/10/2025
Hansa Biopharma to host Q3 2025 interim results conference call
08/10/2025
Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025
07/10/2025
Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm
Regulatory press release
02/10/2025
Media articles
Insights
The Power of Hope: Redefining Treatment Decisions for Highly Sensitized Kidney Patients
07/08/2025
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Patients' perspective
Life on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Patients' perspective
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
